{"id":58320,"date":"2026-02-27T20:46:33","date_gmt":"2026-02-27T12:46:33","guid":{"rendered":"https:\/\/flcube.com\/?p=58320"},"modified":"2026-02-27T20:46:35","modified_gmt":"2026-02-27T12:46:35","slug":"tonghua-dongbao-partners-with-huisheng-biopharma-secures-china-rights-to-first-domestic-insulin-degludec-biosimilars","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58320","title":{"rendered":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars"},"content":{"rendered":"\n<p><strong>Tonghua Dongbao Pharmaceuticals Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600867:SHA\">SHA:\u202f600867<\/a>)<\/strong> and <strong>Huisheng Biopharmaceutical Co., Ltd.<\/strong> announced a <strong>Commercialization Cooperation Agreement<\/strong> to jointly advance <strong>diabetes treatment<\/strong> in China. Under the agreement, Tonghua Dongbao secured <strong>exclusive commercialization rights<\/strong> in <strong>Mainland China<\/strong> for <strong>Huiyoujia (Insulin Degludec\/Insulin Aspart)<\/strong> and <strong>Huiyouda (Insulin Degludec)<\/strong>\u2014the <strong>first domestically produced biosimilars<\/strong> of these next\u2011generation basal insulins.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner 1<\/strong><\/td><td>Tonghua Dongbao Pharmaceuticals (SHA:\u202f600867)<\/td><\/tr><tr><td><strong>Partner 2<\/strong><\/td><td>Huisheng Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Commercialization cooperation<\/td><\/tr><tr><td><strong>Licensed Products<\/strong><\/td><td>Huiyoujia (70% degludec + 30% aspart); Huiyouda (degludec)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive)<\/td><\/tr><tr><td><strong>Tonghua Dongbao Role<\/strong><\/td><td>Commercialization, market promotion, clinical application<\/td><\/tr><tr><td><strong>Huisheng Role<\/strong><\/td><td>R&amp;D, technology, manufacturing supply<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profiles\">Product Profiles<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Composition<\/th><th>Innovation Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Huiyoujia<\/strong><\/td><td>70% insulin degludec + 30% insulin aspart<\/td><td><strong>First domestically produced biosimilar<\/strong> of dual\u2011insulin preparation in China<\/td><\/tr><tr><td><strong>Huiyouda<\/strong><\/td><td>Insulin degludec (ultra\u2011long\u2011acting basal)<\/td><td><strong>First domestic degludec biosimilar<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Resource Complementarity:<\/strong> Tonghua Dongbao brings <strong>established endocrinology commercial infrastructure<\/strong> (insulin glargine, recombinant human insulin market presence); Huisheng provides <strong>biosimilar R&amp;D and manufacturing expertise<\/strong>.<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> As the <strong>first domestic degludec biosimilars<\/strong>, Huiyoujia and Huiyouda can capture market share from <strong>Novo Nordisk&#8217;s originator products<\/strong> (Tresiba, Ryzodeg) before additional competitors enter.<\/li>\n\n\n\n<li><strong>Next\u2011Generation Insulin Access:<\/strong> Insulin degludec offers <strong>flat pharmacokinetic profiles<\/strong> and <strong>flexible dosing<\/strong> vs. older basal insulins; domestic production improves <strong>supply security<\/strong> and <strong>pricing competitiveness<\/strong> in China&#8217;s diabetes market.<\/li>\n\n\n\n<li><strong>Diabetes Market Growth:<\/strong> China has <strong>>\u202f140\u202fmillion diabetes patients<\/strong>; insulin degludec adoption is accelerating as physicians and patients seek <strong>reduced hypoglycemia risk<\/strong> and <strong>improved adherence<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>China Insulin Market<\/strong><\/td><td>~\u202fRMB\u202f20\u202fbillion; dominated by Novo Nordisk, Eli Lilly, Sanofi; biosimilar entry accelerating<\/td><\/tr><tr><td><strong>Degludec Differentiation<\/strong><\/td><td>Ultra\u2011long duration (42+ hours); lower nocturnal hypoglycemia vs. glargine; growing preference in type\u202f1 and type\u202f2 diabetes<\/td><\/tr><tr><td><strong>Tonghua Dongbao Position<\/strong><\/td><td>Leading domestic insulin manufacturer; Huiyoujia\/Huiyouda addition strengthens portfolio vs. Gan &amp; Lee, Jiangsu Hengrui<\/td><\/tr><tr><td><strong>National Reimbursement<\/strong><\/td><td>Biosimilar pricing advantages support NRDL inclusion and volume expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market share capture, and manufacturing scale\u2011up. Actual results may differ due to risks including originator pricing responses, regulatory inspections, and competitive biosimilar launches.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58321,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,3662,861,441],"class_list":["post-58320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-diabetes","tag-huisheng-biopharmaceutical","tag-sha-600867","tag-tonghua-dongbao-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec\/Insulin Aspart) and Huiyouda (Insulin Degludec)\u2014the first domestically produced biosimilars of these next\u2011generation basal insulins.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58320\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars\" \/>\n<meta property=\"og:description\" content=\"Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec\/Insulin Aspart) and Huiyouda (Insulin Degludec)\u2014the first domestically produced biosimilars of these next\u2011generation basal insulins.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58320\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T12:46:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T12:46:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars\",\"datePublished\":\"2026-02-27T12:46:33+00:00\",\"dateModified\":\"2026-02-27T12:46:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320\"},\"wordCount\":364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2707.webp\",\"keywords\":[\"Diabetes\",\"HuiSheng Biopharmaceutical\",\"SHA: 600867\",\"Tonghua Dongbao Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58320#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58320\",\"name\":\"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2707.webp\",\"datePublished\":\"2026-02-27T12:46:33+00:00\",\"dateModified\":\"2026-02-27T12:46:35+00:00\",\"description\":\"Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec\\\/Insulin Aspart) and Huiyouda (Insulin Degludec)\u2014the first domestically produced biosimilars of these next\u2011generation basal insulins.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58320\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2707.webp\",\"width\":1080,\"height\":608,\"caption\":\"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58320#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars - Insight, China&#039;s Pharmaceutical Industry","description":"Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec\/Insulin Aspart) and Huiyouda (Insulin Degludec)\u2014the first domestically produced biosimilars of these next\u2011generation basal insulins.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58320","og_locale":"en_US","og_type":"article","og_title":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars","og_description":"Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec\/Insulin Aspart) and Huiyouda (Insulin Degludec)\u2014the first domestically produced biosimilars of these next\u2011generation basal insulins.","og_url":"https:\/\/flcube.com\/?p=58320","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-27T12:46:33+00:00","article_modified_time":"2026-02-27T12:46:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58320#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58320"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars","datePublished":"2026-02-27T12:46:33+00:00","dateModified":"2026-02-27T12:46:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58320"},"wordCount":364,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58320#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp","keywords":["Diabetes","HuiSheng Biopharmaceutical","SHA: 600867","Tonghua Dongbao Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58320#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58320","url":"https:\/\/flcube.com\/?p=58320","name":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58320#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58320#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp","datePublished":"2026-02-27T12:46:33+00:00","dateModified":"2026-02-27T12:46:35+00:00","description":"Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA:\u202f600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec\/Insulin Aspart) and Huiyouda (Insulin Degludec)\u2014the first domestically produced biosimilars of these next\u2011generation basal insulins.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58320#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58320"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58320#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp","width":1080,"height":608,"caption":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58320#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tonghua Dongbao Partners with Huisheng Biopharma \u2013 Secures China Rights to First Domestic Insulin Degludec Biosimilars"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58320"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58320\/revisions"}],"predecessor-version":[{"id":58322,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58320\/revisions\/58322"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58321"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}